Medicine
Enalaprilat 2.5 mg/2 mL injection
Enalaprilat 2.5 mg/2 mL injection is a generic prescription medicine for intravenous use, made by 2 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77 °F), excursions permitted to 15º to 30ºC (59º to 86°F).
Key facts
- Active ingredient (INN)
- Enalaprilat
- Brand
- Sold under the generic name
- Strength
- 2.5 mg/2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 10 vials of 2 mL
- Manufacturers
- Dr. Reddy's LaboratoriesIndiaHikma Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77 °F), excursions permitted to 15º to 30ºC (59º to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 December 2008
- Identifiers
- RxCUI 1729200, 1729205DailyMed set ID eabae489-e254-4987-ab90-7cda20a6f856, 5d398da1-020c-ccb1-a775-ce8e0b29d621NDC 0143-9786, 43598-169Application ANDA078687, ANDA075578
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 vial in 1 carton / 2 mL in 1 vial | 43598-169-58 | Dr. Reddy's LaboratoriesIndia | 6 June 2023 |
| 10 vial in 1 carton / 2 mL in 1 vial | 0143-9786-10 | Hikma Pharmaceuticals | 23 December 2008 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 9 February 1988 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Enalaprilat
Clinical summary
Enalaprilat is an angiotensin converting enzyme inhibitor indicated for the treatment of hypertension when oral therapy is not practical. It is available as injection for intravenous use. MedsAcross supplies Enalaprilat for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EnalaprilatFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Enalaprilat prescribing information (Dr. Reddy's Laboratories) · U.S. National Library of Medicine, DailyMed
Need Enalaprilat 2.5 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.